288 related articles for article (PubMed ID: 31203242)
21. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
22. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.
Krause MW; Raja R; Agarwal A; Silver MR; Scarlata D; Sciarra A; Kewalramani R
Drugs Aging; 2009; 26(8):665-75. PubMed ID: 19685932
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
24. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
[TBL] [Abstract][Full Text] [Related]
25. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
[TBL] [Abstract][Full Text] [Related]
26. Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study.
Akizawa T; Nobori K; Matsuda Y; Taki K; Hayashi Y; Hayasaki T; Yamamoto H
Ther Apher Dial; 2022 Apr; 26(2):368-377. PubMed ID: 34310049
[TBL] [Abstract][Full Text] [Related]
27. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial.
Sinha SD; Bandi VK; Bheemareddy BR; Thakur P; Chary S; Mehta K; Pinnamareddy VR; Pandey R; Sreepada S; Durugkar S
BMC Nephrol; 2019 Mar; 20(1):90. PubMed ID: 30866856
[TBL] [Abstract][Full Text] [Related]
29. Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Lentini S; Kaiser A; Kapsa S; Matsuno K; van der Mey D
Eur J Clin Pharmacol; 2020 Feb; 76(2):185-197. PubMed ID: 31919558
[TBL] [Abstract][Full Text] [Related]
30. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
Macdougall IC; Walker R; Provenzano R; de Alvaro F; Locay HR; Nader PC; Locatelli F; Dougherty FC; Beyer U;
Clin J Am Soc Nephrol; 2008 Mar; 3(2):337-47. PubMed ID: 18287255
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of C.E.R.A. in Routine Clinical Practice for Correction of Anaemia and Maintenance of the Haemoglobin Levels in CKD Patients not on Dialysis.
Promod PJ; Deshpande R; Mohanty NK; Kulkarni S; Shah HA; Ganju A; Kukreja A; Joshi S
J Assoc Physicians India; 2017 Mar; 65(3):52-57. PubMed ID: 28462544
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
[TBL] [Abstract][Full Text] [Related]
33. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
Alsalimy N; Awaisu A
Int J Clin Pharm; 2014 Dec; 36(6):1115-25. PubMed ID: 25288147
[TBL] [Abstract][Full Text] [Related]
34. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
[TBL] [Abstract][Full Text] [Related]
35. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
37. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
[TBL] [Abstract][Full Text] [Related]
38. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S
Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507
[TBL] [Abstract][Full Text] [Related]
39. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
[TBL] [Abstract][Full Text] [Related]
40. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
